Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients
Authors
Doebele, RPerez, L
Trinh, H
Martinec, M
Martina, R
Riehl, T
Krebs, Matthew G
Meropol, N
Wong, W
Crane, G
Affiliation
University of Colorado, Aurora, CO/US,Issue Date
2019
Metadata
Show full item recordCitation
Doebele R, Perez L, Trinh H, Martinec M, Martina R, Riehl T, et al. P1.01-83 Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients. Journal of Thoracic Oncology. 2019;14(10):S392.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2019.08.798Additional Links
https://dx.doi.org/10.1016/j.jtho.2019.08.798Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2019.08.798